Reimbursed Care Access in Gambia

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Gambian drug regulatory and enforcement framework (Drug Control Act / DLEAG) treats unauthorized possession, trafficking and supply of controlled psychoactive substances as criminal offences; there is no public record of a national medical programme or reimbursement pathway for psilocybin-based therapies. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no publicly available evidence of MDMA-assisted therapy programmes, regulatory approvals, or reimbursement mechanisms in The Gambia; therefore access would be limited to formally authorised clinical trials (if any) subject to approval by the national regulator and ethics authorities. # #

There is no public record of marketing approval or an established reimbursement pathway for esketamine (e.g., Spravato) in The Gambia. The national medicines regulator (Medicines Control Agency) is the competent authority for product registration, and there are no accessible MCA publications or product listings indicating esketamine approval or public reimbursement; consequently esketamine is not part of routine, reimbursed mental health care in the country and would only be available if introduced under an authorised import/compassionate-use programme or within a registered clinical trial. # #

Ketamine is widely used as an essential anaesthetic agent in Gambian health facilities and is part of routine surgical and emergency care in both public and private hospitals; national facility surveys have documented ketamine‑based intravenous anaesthesia as the most commonly available anaesthetic modality in referral facilities. This reflects ketamine’s role as an essential, low-resource anaesthetic in The Gambia’s health system rather than as an authorised, reimbursed psychiatric psychedelic product. #

Regulatory and reimbursement context: the Medicines Control Agency (MCA) is responsible for marketing authorisation and the Ministry of Health is implementing national medicine policies and a Health Financing Strategy (2019–2024) while the country works toward a National Health Insurance Scheme; current financing remains heavily reliant on out-of-pocket payments with limited formal reimbursement for specialty drugs. Thus ketamine’s use for anaesthesia is delivered within the public hospital system (and in private facilities) and financed primarily through existing facility budgets and out-of-pocket payments or limited scheme coverage—not through a dedicated national psychiatric ketamine reimbursement programme. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public record of clinical programmes, regulatory approvals, or reimbursement for DMT in The Gambia. Access would be restricted to any formally authorised clinical research subject to MCA and ethics approvals. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There are no known, authorised therapeutic programmes or reimbursement arrangements for 5‑MeO‑DMT in The Gambia; possession or supply outside regulatory authorisation would be criminalised under national drug control legislation. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of sanctioned ibogaine treatment programmes, regulatory approval, or reimbursement in The Gambia. Any use would be limited to authorised clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The traditional brew (ayahuasca) contains DMT and MAOI-containing plant components and would fall under control provisions; there is no regulatory pathway or reimbursement mechanism for ayahuasca therapy in The Gambia. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline-containing cacti and isolated mescaline have no recognised medical programme or reimbursement status in The Gambia. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The family of 2C compounds is covered by generic/scheduling provisions under many national drug control laws; there is no authorised medical or reimbursed access in The Gambia. #